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Reactive oxygen species (ROS) are generated during nor-
mal cell physiology; however increased ROS formations
are highly detrimental in many cardiometabolic disorders,
including atherosclerosis, hypertension, diabetes, obesity,
neurodegenerative diseases, and aneurism [1–3]. Despite the
numerous existing data the role of ROS and the associated
redox mechanisms of the disease inception and progression
remain elusive. A common feature of all cardiovascular
disorders is the occurrence of oxidative stress, a condition
characterized by an imbalance between ROS production
and the ability of biological systems to detoxify the reactive
intermediates [4]. Produced in excess, ROS react indis-
criminately and cause irreversible damage of the majority
of biological molecules, thereby altering cell functions [5].
Although extensive studies have focused on the redox control
of vascular response to inflammatory and metabolic insults,
the molecular mechanisms ROS generation and the way that
this class of molecules contributes to vascular damage are not
entirely clear. Therefore, uncovering the intimate molecular
control mechanisms involved in regulation of the delicate
balance of ROS formation and neutralization in the vascular
wall cells is a prerequisite for the development of an eﬀective
antioxidative stress therapy.
The topic of this special issue focuses on recent advances
in experimental aspects of oxidative stress in cardiovascular
disorders. In the current issue, H. Osorio et al. have
addressed the role of sodium-glucose cotransporter (SGLT2)
in the oxidative and nitrative stress processes taking place
in the kidney of diabetic rats. The authors have shown that
SGLT2 inhibition reverse streptozotocin-induced diabetes
and redox disbalance in the kidney, suggesting the potential
therapeutic role of SGLT2 inhibitors in diabetic nephropathy.
The role of oxygen supplementation in systemic redox
balance in rats has been investigated in the paper by F.
Nagatomo et al. The authors demonstrated that exposure to
oxygen concentrations higher than 40% leads to a prooxidant
response able to produce morphological changes in red
blood cells, whereas antioxidant response does not seem
to be modified in the 24 h period of the study. J. Dudka
et al. have evaluated the implication of hypothyreosis on
the oxidative stress induced by doxorubicin. The authors
also analyzed the eﬀect of both hypothyreosis and the
drug on cytochrome P450 NADPH-reductase and inducible
nitric oxide synthase expression. The results of this study
bring additional support that hipothyroid conditions may
increase the cardiac oxidative stress caused by doxorubicin.
In the paper by M. Al-Shebly and M. Mansour the authors
have analyzed whether oxidative stress status is modified
in hypertensive/diabetic women during labor. The findings
of this study clearly demonstrate that diﬀerent biomarkers
of redox balance-altered in hypertensive/diabetic women
during labor and suggest that this redox imbalance could
increase the risk of fetal abnormalities. In the paper of
S. Muhammad et al., the authors aimed at investigating
the antioxidant eﬀects of mineral elements supplementation
using a rat model of hypertension. They showed that
copper, manganese, and zinc supplementation reduces the
blood pressure as compared with hypertensive control.
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In addition, a significant reduction in the plasma total
cholesterol, triglyceride, low density lipoprotein-cholesterol,
very low density lipoprotein-cholesterol, malondialdehyde,
and insulin level, as well as increases in the high density
lipoprotein cholesterol, total antioxidant activities, and nitric
oxide have been demonstrated in the supplemented groups
relative to the hypertensive control. Together, the present
report highlights that various minerals may play a role in
preventing oxidative stress, dyslipidemia, and insulin resis-
tance associated with hypertension. Interestingly, R.Wu et al.
demonstrated the beneficial eﬀects of chronic acetylsalicylic
acid (ASA) treatment on cardiac hypertrophy and oxidative
stress in cardiomyopathic hamsters. The authors concluded
that ASA present a therapeutic potential to prevent cardiac
dysfunction.
The review of J. Madrigal-Matute et al. is focused on
the thioredoxin (TRX) system, which is composed of several
proteins such as TRX and Peroxiredoxin (PRDX). In addition
to their main role as antioxidants, recent data highlights their
function in several processes involved on the development
of atherothrombosis. In fact, since TRX and PRDX are
present in the atherosclerotic plaque and can be secreted
under prooxidative conditions to the circulation, their
role as diagnostic, prognostic, and therapeutic biomarkers
of cardiovascular diseases (CVD) has been addressed. In
conclusion, J. Madrigal-Matute et al. summarized several
findings that demonstrate the major role of the TRX system
in the maintenance of the redox status in CVD. Furthermore,
the extracellular levels of PRDX/TRX seem to be related with
a pro-oxidative scenario suggesting their potential role as
biomarkers for oxidative related diseases. Nevertheless, their
value as useful therapeutic tools is being tested and future
studies are necessary to validate its prospective beneficial
eﬀects in CVD.
Vascular NADPH oxidases (Nox) are a class of het-
erooligomeric enzymes, whose unique function is the gen-
eration of ROS in a highly regulated manner [6]; conversely,
the specific role of each enzyme is yet to be discovered. Nox
expression and activity are significantly upregulated in the
vasculature of hypertensive subjects and are associated with
the development of macro- and microvascular diseases [7].
Since the members of the Nox family are major triggers of
oxidative stress they have a prominent role in the pathology
of diabetes-induced vasculopathies [8, 9]; thus, Nox and their
upstream regulators may become important therapeutic
targets [10]. In the paper of J. Miguel-Carrasco et al., the
authors investigated the eﬀects of the profibrotic factor TGF-
beta 1 in mediating Nox overactivity and oxidative stress in
hypertensive rats. The results showed that pharmacological
inhibition of TGF-beta 1 pathway greatly reduces the Nox
activity, expression of the Nox2 and Nox4 isoforms, and
nitrotyrosine levels in hypertensive rats compared to control
animals. Collectively, the data of this study provides con-
clusive evidence on the involvement of this enzyme in the
profibrotic actions of TGF-beta 1.
The major cause for diastolic heart failure is cardiac
aging, which is referred to a dramatic decline in cardiac
pump function with advanced age and resulted in diastolic
dysfunction. Current clinical treatment for patients with
diastolic heart failure is disappointing. The cardioprotective
eﬀects of EGB761, a standard extract from the leaves
of Ginkgo biloba, have been demonstrated already. The
aim of the present study was to investigate the potential
antiaging-associated cellular diastolic dysfunction eﬀects
of EGB761, exploring underlying molecular mechanisms.
Cardiomyocyte aging model was established by treating with
D-galactose. Treatment with EGB761 attenuated the intra-
cellular formation of AGEs, delays the cellular senescence,
and increase reuptake of Ca2+ stores in the sarcoplasmic
reticulum. J. Liu et al. have suggested that EGB761 may
protect against aging-associated diastolic dysfunction in
cardiomyocytes. Furthermore, it was possible that EGB761
could upregulate SERCA2a function through improvement
of the amount of Ser16 sites PLN phosphorylation. In con-
clusion, EGB761 significantly improved the diastolic func-
tion in cardiomyocytes, through the regulation of myocardial
sarcoplasmic reticulum calcium transport regulatory.
NF-E2-related factor 2 (Nrf2) represents a promising
therapeutic target to prevent oxidative stress and oxidative
damage in various pathologies, including cardiovascular
diseases. In the study of E. Donovan et al., the beneficial
eﬀects of phytochemicals included in dietary supplements
might be an eﬀective strategy to protect the cells against
the detrimental eﬀects of oxidative stress. The authors have
demonstrated the Protandim activates Nrf2, a condition
that ultimately influenced the protection of human coronary
artery endothelial cells against an oxidative challenge.
In the paper by A. Ashour et al., the authors have
addressed the potential use of metformin to prevent car-
diotoxic eﬀects of doxorubicin, a potent antitumor agent,
in an experimental model of cardiomyopathy in rats. The
adverse eﬀects of doxorubicin include biochemical and mor-
phological cardiac markers of injury, associated to decreasing
antioxidant systems. Interestingly, the authors demonstrated
that treatment with metformin prevents deleterious changes
associated to doxorubicin mainly by modulation of redox
balance.
Collectively, the original articles published in this special
issue stimulate the ongoing eﬀorts to identify the basic
molecular mechanisms regulating the oxidative stress that
may be used to find ways to manage its occurrence and
correct its adverse eﬀects.
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